Press releases

These press releases are intended for business journalists and analysts/investors

Incruse® Ellipta® (umeclidinium) approved in Australia for Chronic Obstructive Pulmonary Disease

GlaxoSmithKline has announced today that the Therapeutic Goods Administration (TGA) has approved Incruse® Ellipta® (umeclidinium), a maintenance treatment to relieve symptoms in Australian adult patients with chronic obstructive pulmonary disease (COPD), also known as “chronic bronchitis,” “smoker’s cough” or “emphysema”.

Read more - Incruse® Ellipta® (umeclidinium) approved in Australia for Chronic Obstructive Pulmonary Disease Read more

Anoro® Ellipta® approved in Australia for Chronic Obstructive Pulmonary Disease

GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) have proudly announced that the Therapeutic Goods Administration (TGA) has approved Anoro® Ellipta® (umeclidinium/vilanterol) as a maintenance bronchodilator treatment to relieve symptoms in Australian adult patients with chronic obstructive pulmonary disease (COPD) which is also known as “chronic bronchitis,” “smoker’s cough” or emphysema”.

Read more - Anoro® Ellipta® approved in Australia for Chronic Obstructive Pulmonary Disease Read more